Skip to main content

Currently Skimming:

Appendix B Workshop Agenda
Pages 77-86

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 77...
... While several initiatives are underway to enhance pain research and improve care in the country, including the National Institutes of Health (NIH) Pain Consortium and Interagency Pain Research Coordinating Committee's National Pain Strategy, additional efforts are needed to foster collaborations between the public and private sectors in 77
From page 78...
... NIH is joining with private partners in the pharmaceutical industry and the research community to launch an opioid research initiative with the goal of cutting in half the amount of time required to develop new therapies for (1) safe, more effective strategies for pain management; (2)
From page 79...
... The Federal Pain Research Strategy: An Overview LINDA PORTER, National Institute of Neurological Disorders and Stroke 2:40 p.m. Discussion Among Speakers and Workshop Participants 3:10 p.m.
From page 80...
... 3:25 p.m. Session Overview NORA VOLKOW, National Institute on Drug Abuse (Moderator)
From page 81...
... Identifying Potential Targets for Pain Management Using Human Cells/Organoids, Tissue CLIFFORD WOOLF, Harvard Medical School 9:15 a.m. Monitoring and Modulating Circuit Activity in Pain Promise of the BRAIN Initiative ROBERT GEREAU, Washington University in St.
From page 82...
... Discussion Among Speakers and Workshop Participants: Launching Public–Private Partnerships to Accelerate the Development of Therapeutics for Non-Addictive Pain Medicines 11:15 a.m. BREAK SESSION III: ADDRESSING CLINICAL CHALLENGES AND IMMEDIATE NEEDS Objectives: Discuss challenges and opportunities to identifying and validating objective biomarkers of pain, including approaches focusing on homogenous populations.
From page 83...
... PANEL: How to implement a targeted approach to therapy development by focusing on homogenous populations; dissecting pain mechanisms and clinical research in specific pain conditions -- natural history biomarkers, clinical trial readiness. KATHERINE DAWSON, Biogen SHARON HERTZ, Food and Drug Administration SEAN MACKEY, Stanford University WILLIAM MAIXNER, Duke University KEN VERBURG (via WebEx)
From page 84...
... ROBERT DWORKIN, University of Rochester Medical Center PETRA KAUFMANN, National Center for Advancing Translational Sciences SCOTT POWERS, Cincinnati Children's Hospital 3:15 p.m. Discussion Among Speakers and Workshop Participants: Launching Public–Private Partnerships to Advance Clinical Work in Understanding and Treating the Transition from Acute to Chronic Pain 3:45 p.m.
From page 85...
... APPENDIX B 85 SHARI LING, Centers for Medicare & Medicaid Services ANDREY OSTROVSKY, Center for Medicaid and CHIP Services 4:25 p.m. Discussion Among Moderators and Workshop Participants 4:55 p.m.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.